An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design

Am Heart J. 2010 May;159(5):705-9. doi: 10.1016/j.ahj.2010.03.004. Epub 2010 Mar 15.

Authors

Robert M Califf, Yuliya Lokhnygina, Christopher P Cannon, Michael E Stepanavage, Carolyn H McCabe, Thomas A Musliner, Richard C Pasternak, Michael A Blazing, Robert P Giugliano, Robert A Harrington, Eugene Braunwald

PMID: 20435175
DOI: 10.1016/j.ahj.2010.03.004

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Acute Coronary Syndrome / blood
Acute Coronary Syndrome / drug therapy*
Azetidines / therapeutic use*
Cholesterol, LDL / blood
Drug Combinations
Ezetimibe, Simvastatin Drug Combination
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Models, Statistical
Patient Compliance
Research Design
Simvastatin / therapeutic use*
Treatment Outcome

Substances

Azetidines
Cholesterol, LDL
Drug Combinations
Ezetimibe, Simvastatin Drug Combination
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Simvastatin